BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22319035)

  • 1. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.
    Birzniece V; Sutanto S; Ho KK
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E521-7. PubMed ID: 22319035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men.
    Birzniece V; Sata A; Sutanto S; Ho KK
    J Clin Endocrinol Metab; 2010 Dec; 95(12):5443-8. PubMed ID: 20843951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paracrine regulation of growth hormone secretion by estrogen in women.
    Birzniece V; Sata A; Sutanto S; Ho KK
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3771-6. PubMed ID: 20444909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women.
    Gibney J; Johannsson G; Leung KC; Ho KK
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3897-903. PubMed ID: 15855258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes.
    Birzniece V; Ho KK
    Eur J Endocrinol; 2015 Oct; 173(4):479-87. PubMed ID: 26199431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women.
    Birzniece V; Meinhardt U; Gibney J; Johannsson G; Baxter RC; Seibel MJ; Ho KK
    J Clin Endocrinol Metab; 2010 May; 95(5):2099-106. PubMed ID: 20207825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer.
    De Marinis L; Mancini A; Izzi D; Bianchi A; Giampietro A; Fusco A; Liberale I; Rossi S; Valle D
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):681-5. PubMed ID: 10848871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.
    Birzniece V; Meinhardt UJ; Gibney J; Johannsson G; Armstrong N; Baxter RC; Ho KK
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1005-12. PubMed ID: 22170716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G; Weekers F; Baxter RC; Wouters P; Iranmanesh A; Bouillon R; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
    Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.
    Tsourdi E; Kourtis A; Farmakiotis D; Katsikis I; Salmas M; Panidis D
    Fertil Steril; 2009 Apr; 91(4 Suppl):1427-30. PubMed ID: 18692782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparate Effect of Aromatization on the Central Regulation of GH Secretion by Estrogens in Men and Postmenopausal Women.
    Birzniece V; McLean M; Reddy N; Ho KKY
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2978-2984. PubMed ID: 30920620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement.
    Span JP; Pieters GF; Sweep CG; Hermus AR; Smals AG
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1121-5. PubMed ID: 10720049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting.
    Grinspoon S; Corcoran C; Stanley T; Katznelson L; Klibanski A
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4251-6. PubMed ID: 9851759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men.
    Gentili A; Mulligan T; Godschalk M; Clore J; Patrie J; Iranmanesh A; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Feb; 87(2):825-34. PubMed ID: 11836328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term modulation of the androgen milieu alters pulsatile, but not exercise- or growth hormone (GH)-releasing hormone-stimulated GH secretion in healthy men: impact of gonadal steroid and GH secretory changes on metabolic outcomes.
    Fryburg DA; Weltman A; Jahn LA; Weltman JY; Samojlik E; Hintz RL; Veldhuis JD
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3710-9. PubMed ID: 9360530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
    Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
    Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women.
    Ovesen P; Vahl N; Fisker S; Veldhuis JD; Christiansen JS; Jørgensen JO
    J Clin Endocrinol Metab; 1998 May; 83(5):1662-7. PubMed ID: 9589674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tamoxifen and testosterone propionate in male rats: differential prevention of orchidectomy effects on sex organs, bone mass, growth, and the growth hormone-IGF-I axis.
    Fitts JM; Klein RM; Powers CA
    J Androl; 2004; 25(4):523-34. PubMed ID: 15223841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of dose and route of estrogen administration on the somatotropic axis in normal women.
    Lissett CA; Shalet SM
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4668-72. PubMed ID: 14557438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.